ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that Ms.Tracy(Ziyi) Song has been appointed as the Chief Financial Officer (CFO) of the company, reporting to Dr. Wenzhi Tian, Chairman and founder of ImmuneOnco. Ms. Song will be responsible for the IPO financial transactions and financial strategy of ImmuneOnco.

Ms. Song holds a bachelor's degree in Economics and Mathematics from the University of Chicago in the United States. She has over 15 years of experience in international investment banking and investment management in the medical field. She has rich capital market experience in IPO, financing, M&A and other capital markets, and was responsible for the completion of more than 50 capital market transactions during her investment banking. Prior to joining ImmuneOnco, Ms. Song held key positions at Bank of America Merrill Lynch, UBS and CITIC Lyon. She was responsible for investment strategy planning and investment management in the fund of healthcare industry in the Greater Bay Area Fund. She will receive a Master's degree in Medicine from the School of Medicine of Hong Kong University.

Ms. Song said, "It is a great honor to join ImmuneOnco, which has leading technology and R&D capabilities, a first-class team and a globally competitive oncology innovative drug pipeline platform. I am fully confident in ImmuneOnco’s future. I look forward to working with ImmuneOnco to promote the rapid development of investment and financing business together and make my best contribution to the international development of ImmuneOnco."

Dr. Tian Wenzhi, the Chairman and founder, said, "I am very pleased to welcome Tracy to join the team of ImmuneOnco. I believe that she will definitely help the company to enter the capital market smoothly with her rich professional experience. We also look forward to her joining us to accelerate the realization of ImmuneOnco with great vision of 'developing first-class new drugs for the benefit of cancer patients'." "We will work with all our colleagues to build the company into a world-renowned biopharmaceutical company, and develop first-in-class anti-cancer drugs for cancer patients around the world".